



## 4everProtein

c/o INiTS

Media Quarter Marx 3.2

Maria-Jacobi-Gasse 1

1030 Wien | Austria

contact: Dr. Anton Bauer, MBA

p: +43-699-17186417

e: anton.bauer@4everProtein.com

www.4everProtein.com

(under construction)

company is not yet incorporated

**Industry:** Biotechnology

### Funding:

raised over the past 10 years funding for prototype and platform development in academic-private partnerships and secured IP and patent rights

seeking initial funding: €500k

### Use of Proceeds:

- equity leverage for public funding
- recruitment
- product development
- broaden IP portfolio

### Competitive Advantage:

- defensible IP
- domain expertise (therapeutic antibodies, recombinant protein production and cell line development)
- unique prototype
- unique platform

### Founder Team:

- Dr. Anton Bauer, MBA
- Univ.Prof. Dr. Emilio Casanova

## The Global Challenge

Respiratory diseases caused by viral infections have been a challenge since early days of mankind and thus long before SARS-CoV2 emerged. Although various valuable approaches such as prophylactic vaccinations and therapeutic treatments have been developed to confer protection, severe diseases, annual Influenza epidemics or the current pandemic could not be prevented. Monoclonal antibodies (mAbs) have successfully been developed to treat cancer, inflammatory and autoimmune diseases and are parenterally applied. Current mAbs against infectious diseases are produced in their classical form and therefore parenterally applied causing that only a very small fraction reaches the site of infection. Thus their benefit and use of application is very limited.

## Our Solution

Applying protection via the same route and directly at the site of infection provides an advantage over parenteral treatment. This requires development and production of suitable therapeutics, which are effective and stable at the mucosa, which is lining our primary site of infection. We have developed a prototype for superior protection, which is based on the same mechanism (mucosal antibodies) that safeguard healthy individuals from an infection. This allows nasal and pulmonary delivery beneficial due to being patient-friendly, noninvasive, immediately protective, cost-effective, and less side effects.

## Market

We plan to enter the existing market of biologics for Nasal&Inhalation delivery and expand it by introducing mucosal antibodies and mucosal antibody-like molecules. In this multi-billion dollar market and our SAM is 390 M.

## Competitive Landscape

Mucosal antibodies are complex and difficult-to-produce proteins. Various previous approaches from competitors to produce such type of proteins took long and resulted in inefficient production. We have successfully developed a prototype mucosal antibody with unprecedented efficiency and titer based on our GMP validated BESTcell platform which allows fast and efficient production of therapeutic proteins. We have gained know-how and secured the platform IP.

## Business Model

Identify and develop mucosal therapeutics against respiratory infections and secure intellectual property. Enter into business partnerships with successful companies with market products in the field and co-develop therapeutics. Leverage BESTcell platform for production of tools required for research and development and for clinical studies.

## Founder Team (cooperate since 20+years)

**Anton Bauer:** combination of 25+ years life sciences expertise, economic education and leadership experience; executive and C-level positions for 15+ years in startup and biotech companies (f-star, The Antibody Lab, Axon, Intercell/Valneva) and cofounder of 2 of these companies; training: Dr. rer. nat. Chemistry/Biochemistry Univ. Vienna; executive global MBA (EU/USA)

**Emilio Casanova:** 25+ years track record in transgenesis, oncology and recombinant technologies; since 2014 Professor at Medical University of Vienna; track record of high level publications; 20+ years in top academic research (DKFZ, Biocenter Basel, Ludwig Boltzmann Institute)

training: Dr. rer. nat. Biology/Molecular Biology/Genetics Univ. Leon, Spain

## Traction to Date

established co-operations; mucosal therapeutic prototype, vast antibody and recombinant protein know how and secured IP; established BESTcell platform used for GMP production of 19 therapeutic proteins (licensed by Polymun); 100+ projects for various diagnostic and therapeutic proteins; 20+years cooperation and friendship of founders